IN8BIO, INC. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a stark contrast between technical scientific potential and fiscal fragility. While the clinical data for the DeltEx platform remains encouraging, the company is operating on a razor-thin margin of error. The transition from a cash-burning developer to a partnership-ready asset depends entirely on the company's ability to secure non-dilutive capital or strategic collaborations before its current reserves are exhausted. Investors are essentially betting on a race between the clinical clock and the financial clock. If the company can successfully navigate the regulatory and funding hurdles to reach the late 2026 data readouts, the upside is significant. However, the 'substantial doubt' language in the filing serves as a critical warning that the path to those milestones is fraught with the risk of insolvency or extreme dilution.